Matthew Shea
Stock Analyst at Needham
(3.96)
# 1,732
Out of 4,495 analysts
37
Total ratings
72%
Success rate
19.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Shea
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TOI The Oncology Institute | Reiterated: Buy | $7 | $5.85 | +19.66% | 8 | Jul 7, 2026 | |
| ASTH Astrana Health | Rated: Buy | $30 → $41 | $46.81 | -12.41% | 3 | May 8, 2026 | |
| EVH Evolent Health | Reiterated: Buy | $4 → $5 | $5.63 | -11.19% | 11 | May 7, 2026 | |
| AGL agilon health | Reiterated: Hold | n/a | $115.67 | - | 8 | May 7, 2026 | |
| PRVA Privia Health Group | Reiterated: Buy | $30 | $27.77 | +8.03% | 7 | May 7, 2026 |
The Oncology Institute
Jul 7, 2026
Reiterated: Buy
Price Target: $7
Current: $5.85
Upside: +19.66%
Astrana Health
May 8, 2026
Rated: Buy
Price Target: $30 → $41
Current: $46.81
Upside: -12.41%
Evolent Health
May 7, 2026
Reiterated: Buy
Price Target: $4 → $5
Current: $5.63
Upside: -11.19%
agilon health
May 7, 2026
Reiterated: Hold
Price Target: n/a
Current: $115.67
Upside: -
Privia Health Group
May 7, 2026
Reiterated: Buy
Price Target: $30
Current: $27.77
Upside: +8.03%